Liver Transplantation in the Management of Colorectal Liver Metastases

Liver Transplantation in the Management of Colorectal Liver Metastases

Summary of CME Lecture by Pål-Dag Line, MD

1. Main Clinical Topics Discussed

• The evolving role of liver transplantation (LT) as a treatment strategy for unresectable colorectal liver metastases (CRLM)
• Patient selection criteria and prognostic scoring for transplant candidacy
• Metabolic tumor biology assessment using PET imaging
• Recurrence patterns and management post-transplant

2. Key Learning Points, Guidelines, and Recommendations

Rationale for Liver Transplantation in CRLM:

• The traditional paradigm classifies ~80% of CRLM patients as unresectable, leaving them with palliative chemotherapy only and a 5-year survival of approximately 10%
• LT eliminates resectability as a barrier; however, rigorous patient selection is essential
• The principle of transplant benefit must be demonstrated: survival gain from LT must substantially exceed best conventional therapy, with an absolute minimum 5-year survival benchmark of ≥50% (speaker advocates for higher)

Prerequisites for Transplant Consideration:

• Liver-only disease confirmed
• Radical resection of the primary tumor
• Absence of BRAF V600E mutation (associated with poor prognosis; newer targeted agents may modify this)
• MSI-high patients are excluded (immunotherapy incompatibility with transplant immunosuppression)
• No N2 lymph node involvement (relative exclusion; requires extended observation period)
• Well/moderately differentiated histology (signet ring cell and undifferentiated tumors excluded)
• Right-sided primary tumors carry universally worse prognosis regardless of treatment modality

International Guidelines (ILTS) — Selection Framework:

• Exclude extrahepatic disease
• Require ≥10% objective radiological response to chemotherapy (RECIST-based; must exceed stable disease threshold)
• Durable, sustained chemotherapy response required
• CEA level <80
• Complete first-line chemotherapy prior to listing
• Minimum observation period of ≥1 year

Oslo Score (OSLO-CoMet Predictive Scoring):

Four adverse parameters (1 point each):

1. Maximum tumor diameter ≥5.5 cm

2. CEA >80 at transplant

3. Progression on chemotherapy

4. Time interval from diagnosis to transplant <2 years

• Oslo score 0–1: Excellent outcomes; recommended transplant candidates
• Oslo score 4: Near-universal mortality within 3.5 years

PET-Based Metabolic Tumor Volume (MTV):

• MTV defined as tumor volume with uptake ≥40% of maximum standardized uptake value (SUVmax), summed across all lesions
• Cut-off values:

- Chemotherapy response: MTV <4.5 cc (favorable)

- Liver resection: MTV <6 cc (100% survival reported)

- Liver transplantation: MTV <70 cc (~12× higher threshold than resection)

• MTV assesses biological tumor burden rather than morphological load — patients with numerous lesions but low MTV can still achieve excellent post-transplant survival
• PET scan must be performed ≥4 weeks off chemotherapy to avoid false-negative metabolic suppression
• MTV modifies the prognostic impact of lesion number and tumor burden score

3. Specific Clinical Data and Study Results